

Regulatory Announcement

Company AKERS BIOSCIENCES INC
TIDM AKR
Headline United States Military Contract
Released 07:00 17-Sep-07

Embargoed: 0700hrs, 17 September 2007

Akers Biosciences, Inc

('ABI' or the 'Company')

Receipt of Further United States Military Contracts

Akers Biosciences, Inc. (LSE:AKR) which develops, manufactures, and supplies rapid, point of care screening and testing products, is pleased to announce that it has received an order from the United States Army for the purchase of its' BreathScan® alcohol safety units. This contract is valued at \$2,500,000 and is deliverable beginning immediately.

The Company has previously stated that it had expected significant orders from several departments of the United States Government as a result of its' efforts to increase safety awareness. ABI continues to anticipate such further orders in the near future. The units provided consist of the Company's unique, patented disposable breathalyzer device housed within its patented, portable and refillable key ring case.

Thomas A. Nicolette, President and CFO of ABI, commented,

'This latest order will take the total number of our BreathScan® alcohol safety units in use by the US Military to over 950,000. This is the beginning of a recurring revenue business model generated from this product line, where the alcohol breathalyzers will continually require replacement as they are used and disposed of. We confidently expect other divisions of the United States Military to introduce our product line over the course of the very near future.

This is the clearest progressive step to date in transforming ABI from a purely research and development company to business that is capitalizing on its proprietary product lines and generating sustainable revenues from them.'

Enquiries:

Akers Biosciences, Inc.

Thomas A. Nicolette, President & CFO

Tel. 001 856 848 2116

Hansard Group

Ben Simons

Tel. 020 7245 1100

Akers Biosciences

Akers Biosciences, Inc. develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcare information both rapidly and directly to the patient or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The company's state-of-the-art rapid diagnostic assays can be performed virtually anywhere in minutes when time is of the essence. Akers has aligned with major healthcare companies and high volume medical products distributors to maximize product offerings, and to be a major worldwide competitor in diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com.

END